CBD Policies From CHPA, CRN Follow FDA; AHPA Acts Ahead Of Agency
Executive Summary
CHPA says FDA's enforcement discretion for hemp and CBD supplements isn't sufficient oversight as potentially unsafe products are available. CRN announces three CBD firms as members, but says "many companies marketing products as containing CBD are not" compliant. Guidance policy adopted in March says AHPA doesn't agree or disagree with FDA but some CBD firms and legal experts assert the agency is "inaccurate, and have presented certain arguments that potentially counter FDA’s position."
You may also be interested in...
As A Botanical, Cannabidiol Was Next Ingredient Up For AHPA's Guidance On Use In Supplements
Leading discussions on CBD safety as a dietary ingredient and developing best-practices guidance were natural steps for AHPA. "We were viewing it as another botanical product, another one of the type of products that we’ve been dealing with throughout our history," said program development director Jane Wilson.
FDA Opens CBD Regulatory Path Docket, Warns Firms On Claims Missteps
With public hearing scheduled May 31 and a related public comment period, FDA "is interested in whether there are particular safety concerns that we should be aware of as we consider the FDA’s regulatory oversight and monitoring" of CBD products. Also influencing FDA's consideration is that CBD and other cannabis-derived substances are approved and being studied as drugs products, making their use as dietary ingredients noncompliant with agency regulations.
FDA Clearing CBD As Dietary Ingredient? Legislation More Likely Than Rulemaking
Senate Appropriations subcommittee members add to Capitol Hill's push for FDA to change its current regulatory stance that CBD is deemed noncompliant for use in supplements and food. Commissioner Gottlieb suggests legislation authorizing FDA to allow use of CBD up to certain concentrations in supplements and food products. FDA currently allows sales of food and supplements containing CBD under enforcement discretion.